OncoResponse Announces Phase 1 Results of OR502 in Advanced Cancer
07 Nov 2024 //
PR NEWSWIRE
OncoResponse to Present OR502 Phase 1 Data at SITC 2024
04 Nov 2024 //
PR NEWSWIRE
OncoResponse Announces Appointment of Carol Gallagher to Board of Directors
06 Sep 2023 //
PR NEWSWIRE
OncoResponse Awarded $13 Million in Funding from CPRIT
18 May 2023 //
PR NEWSWIRE
OncoResponse Presents at AACR 2023 Dual Antagonist Antibodies LILRB1 & LILRB2
19 Apr 2023 //
PR NEWSWIRE